Saturday 17 October 2026 Export ANEB’s income statement to Excel — free account

Anebulo Pharmaceuticals, Inc.

In the quarter to December 2025, EPS grew 44.4% and free cash flow grew 6.58%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

0.00 0.31 −100.00%

Follow ANEB

Alert me

Market cap: $17.6M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 40.98%

Capital & Financial Ratios $m

Market Cap 17.60

Revenue —

Net Income (7.98)

Free Cash Flow (5.84)

Net Debt (9.04)

Current Ratio 6.24

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 10.94%

Next Y EPS Growth (68.42%)

Next Y revenue growth —

Next 5Y EPS Growth (12.86%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'25
Cash	11	3	12	9
Receivables	—	—	0	0
Inventory	—	—	—	—
Other	—	—	—	—
	12	4	12	9

	2023	2024	2025	Q'25
Payables	1	0	0	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	1	0	0	1

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	(8.20%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	(1)	(1)	—	—	—
’25	(2)	(1)	(2)	(2)	(6)
’24	(3)	(2)	(1)	(2)	(8)
’23	(2)	(3)	(2)	(3)	(10)
’22	(1)	(1)	(1)	(2)	(5)
’21	0	0	(1)	(3)	(5)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	(1)	(1)	—	—	—
’25	(2)	(1)	(2)	(2)	(6)
’24	(3)	(2)	(1)	(2)	(8)
’23	(2)	(3)	(2)	(3)	(10)
’22	(1)	(1)	(1)	(2)	(5)
’21	0	0	(1)	(3)	(5)

Fiscal quarters ending in the months shown.

EPS $

	Sep	Dec	Mar	Jun	Year
’26	(0.05)	(0.05)	—	—	—
’25	(0.08)	(0.09)	(0.04)	(0.05)	(0.25)
’24	(0.10)	(0.11)	(0.06)	(0.05)	(0.32)
’23	(0.11)	(0.15)	(0.11)	(0.10)	(0.47)
’22	(0.07)	(0.05)	(0.08)	(0.10)	(0.29)
’21	(0.02)	(0.03)	(0.69)	(1.59)	(2.83)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	4.40	1.77	1.62	0.80	0.90	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	9.33	7.89	4.05	3.30	3.42
People
People	Employees	—	—	—	—	3	3	4	2	3	3
	Revenue/emp, $m	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	—	—	—	—	—	—	—	—
	EBT	—	—	—	—	0	(30)	(7)	(12)	(8)	(8)
	EBT margin, %	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	0	—	—	0	(30)	(7)	(12)	(8)	(8)
	Depreciation	—	—	—	—	—	—	—	—	0	0
Per share, $
Per share, $	Revenue	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	—	—	(0.01)	(2.83)	(0.29)	(0.47)	(0.32)	(0.25)
	Cash flow	—	—	—	—	(0.01)	(0.36)	(0.23)	(0.39)	(0.31)	(0.19)
	Capex	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	—	—	—	—	(0.01)	(0.36)	(0.23)	(0.39)	(0.31)	(0.19)
	Book value	—	—	—	—	(0.01)	1.57	0.65	0.42	0.15	0.34
	Shares, m	—	—	—	—	12	14	23	25	26	34
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	0	(5)	(5)	(10)	(8)	(6)
	Capex	—	—	—	—	—	—	—	—	—	—
	Free cash flow	—	—	—	—	0	(5)	(5)	(10)	(8)	(6)
Balance, $m
Balance, $m	Working capital	—	—	—	—	3	21	15	11	3	11
	Total debt	—	—	—	—	0	—	—	—	—	—
	Net debt	—	—	—	—	(3)	(20)	(15)	(11)	(3)	(12)
	Shareholders’ equity	—	—	—	—	0	21	15	11	4	12
Returns, %
Returns, %	ROA	—	—	—	—	(11.53)	(311.65)	(36.66)	(86.11)	(104.19)	(104.63)
	ROIC	—	—	—	—	0.00	(158.37)	(823.59)	0.00	(722.96)	(19,215.63)
	ROE	—	—	—	—	(1.64)	(362.14)	(37.42)	(91.41)	(113.80)	(109.69)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ATYR aTyr Pharma, Inc.	$18.0M	— (loss-making)	— (loss-making)	−90.75% (below 0%: shrinking)	n/m	+32.22% (above 0%: growing)	100.00%	0.00%	Compare
NEUP Neuphoria Therapeutics Inc.	$17.9M	— (loss-making)	— (loss-making)	−107.32% (below 0%: shrinking)	n/m	+133.86% (above 0%: growing)	100.00%	0.00%	Compare
JSPR Jasper Therapeutics, Inc.	$17.7M	— (loss-making)	—	—	n/m	+55.74% (above 0%: growing)	0.00%	0.00%	Compare
ANEB Anebulo Pharmaceuticals, Inc.	$17.6M	— (loss-making)	—	—	n/m	+6.58% (above 0%: growing)	—	0.00%
ACGN Aceragen, Inc.	$17.1M	— (loss-making)	— (loss-making)	+2,394.95% (above 0%: growing)	n/m	−115.67% (below 0%: shrinking)	100.00%	(834.33%)	Compare
RADX Radiopharm Theranostics Limited - Sponsored ADR	$17.0M	—	—	—	—	−137.75% (below 0%: shrinking)	—	—	Compare
DYAI Dyadic International Inc.	$16.8M	— (loss-making)	— (loss-making)	−0.57% (below 0%: shrinking)	n/m	−1,298.54% (below 0%: shrinking)	(2.39%)	(213.73%)	Compare
PBM Psyence Biomedical Ltd.	$16.5M	0.2×	—	—	n/m	−707.20% (below 0%: shrinking)	—	0.00%	Compare
TCRX TScan Therapeutics, Inc.	$16.2M	— (loss-making)	— (loss-making)	−65.83% (below 0%: shrinking)	n/m	+18.95% (above 0%: growing)	100.00%	(2,901.33%)	Compare
Median of peers	$17.1M	—	—	−65.83%	—	−48.36%	100.00%	0.00%